An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Marion Noret, Aline Dechanet et al.|Clinical Microbiology and Infection|2021Cited by 107
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19Florence Ader, Alexandre Duvignaud, Maude Bouscambert‐Duchamp et al.|The Lancet Infectious Diseases|2022Cited by 21
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2021Cited by 15
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trialDavid M. Smadja, France Mentré, Clément Massonnaud et al.|Scientific Reports|2025Cited by 7